Bilgimol Joseph C, Ragupathi Subbareddy, Vengadassalapathy Lakshmanan, Senthil Nathan S, Selvakumar Kalimuthu, Ganesan M, Manjunath Sadananda Rao
Joseph C Bilgimol, M Ganesan, Sadananda Rao Manjunath, Micro Therapeutic Research Labs Private Limited, Chennai 600059, Tamilnadu, India.
World J Stem Cells. 2015 Sep 26;7(8):1118-26. doi: 10.4252/wjsc.v7.i8.1118.
Stem cells are of global excitement for various diseases including heart diseases. It is worth to understand the mechanism or role of stem cells in the treatment of heart failure. Bone marrow derived stem cells are commonly practiced with an aim to improve the function of the heart. The majority of studies have been conducted with acute myocardial infarction and a few has been investigated with the use of stem cells for treating chronic or dilated cardiomyopathy. Heterogeneity in the treated group using stem cells has greatly emerged. Ever increasing demand for any alternative made is of at most priority for cardiomyopathy. Stem cells are of top priority with the current impact that has generated among physicians. However, meticulous selection of proper source is required since redundancy is clearly evident with the present survey. This review focuses on the methods adopted using stem cells for heart diseases and outcomes that are generated so far with an idea to determine the best therapeutic possibility in order to fulfill the present demand.
干细胞因包括心脏病在内的各种疾病而在全球引发了广泛关注。了解干细胞在治疗心力衰竭中的机制或作用很有必要。骨髓来源的干细胞常用于改善心脏功能。大多数研究是针对急性心肌梗死进行的，少数研究则探讨了使用干细胞治疗慢性或扩张型心肌病的情况。使用干细胞的治疗组中出现了极大的异质性。对于心肌病而言，对任何替代疗法的需求日益增加是最为优先的事项。鉴于干细胞目前在医生中产生的影响，它是最优先考虑的。然而，由于目前的调查中明显存在冗余现象，因此需要精心选择合适的来源。本综述重点关注使用干细胞治疗心脏病所采用的方法以及迄今为止所产生的结果，旨在确定最佳治疗可能性以满足当前需求。
